{"id":"grazaoprevir-elbasavir-rbv","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anemia (ribavirin-related)"},{"rate":null,"effect":"Elevated bilirubin"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a direct-acting antiviral (DAA) combination therapy for hepatitis C. Grazoprevir blocks the NS3/4A serine protease essential for HCV polyprotein processing, while elbasavir targets the NS5A protein required for viral replication and assembly. Ribavirin enhances antiviral activity through multiple mechanisms including mutagenesis of the viral genome.","oneSentence":"Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, and ribavirin acts as a nucleoside analog to inhibit viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:50.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)"}]},"trialDetails":[{"nctId":"NCT03037151","phase":"PHASE4","title":"Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV","status":"UNKNOWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2018-08-01","conditions":"Compensated Cirrhosis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2891,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Grazaoprevir/Elbasavir/RBV","genericName":"Grazaoprevir/Elbasavir/RBV","companyName":"The HIV Netherlands Australia Thailand Research Collaboration","companyId":"the-hiv-netherlands-australia-thailand-research-collaboration","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, and ribavirin acts as a nucleoside analog to inhibit viral replication. Used for Chronic hepatitis C virus infection (genotype 1, 4, 5, 6).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}